Therapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials.
Mark Messak, Ahmed Abdelmageed, Ahmed Noureldeen Abbas et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and random-effects meta-analysis assessed randomized controlled trials of cannabinoids for Parkinson’s disease (PD). Eleven trials were identified, with six contributing poolable outcomes. Pooled results showed no significant improvement in PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27), motor examination, motor experiences of daily living, or non-motor symptoms. A sensitivity analysis suggested that the pooled non-motor symptom estimate was largely driven by nabilone, but did not establish a significant benefit. The authors conclude that cannabinoids have not shown significant benefit in PD.
Key findings
- Across six trials with poolable outcomes, cannabinoids did not significantly improve PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27).
- No significant pooled benefit was found for motor examination, motor experiences of daily living, or non-motor symptoms.
- After excluding Peball et al., the non-motor symptom estimate was SMD = 0.34, 95%CI [-0.19 to 0.88], p = 0.21, suggesting a nabilone-specific signal.
Why it matters
The findings temper expectations that cannabinoids, considered as a group, improve Parkinson’s disease symptoms. The possible nabilone signal for non-motor symptoms is uncertain and should not be treated as evidence of established efficacy. Distinguishing cannabinoid agents and using standardized study protocols may help clarify whether any specific treatment has a clinically relevant effect.
What to keep in mind
Only six of the 11 identified trials had outcomes suitable for meta-analysis; the authors also advise caution and note the need for standardized, pharmacologically stratified studies.